Treatment

The phase 3 PSMAddition trial showed that adding Lutetium Lu 177 vipivotide tetraxetan to standard androgen-deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) significantly improved prostate-specific antigen (PSA) responses in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). The study included 1,144 patients, most with high tumor burden and bone metastases. Researchers previously […]

Treatment for cutaneous T-cell lymphoma (CTCL) is increasingly tailored to disease stage and location. Early-stage skin-only disease is often treated with phototherapy, while advanced disease may require systemic therapies such as romidepsin, pralatrexate, or Brentuximab vedotin. A key option for advanced CTCL is Mogamulizumab-kpkc, particularly for patients with high blood involvement or Sezary syndrome. In

A large real-world study in Japan has confirmed the long-term safety and effectiveness of Darbepoetin Alfa for treating anemia in patients with myelodysplastic syndromes (MDS). The 5-year post-marketing surveillance study followed 1,834 patients across 460 medical centers, providing much broader evidence than the original 2014 approval trial, which included only 52 patients. Researchers found that

The global phase 3 TroFuse-005 trial evaluated Sacituzumab Tirumotecan in 776 patients with advanced or recurrent endometrial cancer or carcinosarcoma whose disease had progressed after platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy. The study compared the drug with physician’s choice chemotherapy, including doxorubicin or paclitaxel. Researchers reported that Sacituzumab Tirumotecan significantly improved both overall survival and progression-free

The phase 3 TALAPRO-2 trial found that radiographic progression-free survival (rPFS) strongly correlates with overall survival (OS) in first-line metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib plus enzalutamide. The study analyzed 805 patients in the overall population, 399 with homologous recombination repair (HRR) gene mutations, and 155 with BRCA1/2 alterations. Researchers reported moderate-to-strong correlations

A Phase 2 study showed that combining Keytruda with BCG therapy achieved strong responses in patients with very high-risk, BCG-naive non–muscle-invasive bladder cancer. Among 37 patients, 92% achieved a clinical complete response at six months, and no patients progressed to muscle-invasive or metastatic disease during follow-up. The 12-month high-grade recurrence-free survival rate was about 88%,

New 3-year results from the phase 3 ENVISION trial show that Zusduri (mitomycin for intravesical solution) can provide long-lasting disease control for patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer. The study found that nearly two-thirds of patients who achieved a complete response after treatment remained cancer-free three years later. Patients received only a single

A 10-year phase 2 study published in the journal Blood found that ibrutinib alone can provide long-lasting benefits for patients with chronic lymphocytic leukemia (CLL), including those with high-risk disease features. The study included 84 patients who were either newly diagnosed or had relapsed disease, many of whom had TP53 abnormalities or unmutated IGHV, both

A real-world study of patients with relapsed or refractory mantle cell lymphoma (MCL) found that the drug Brukinsa may work better than older BTK inhibitors. Researchers reported that patients treated with zanubrutinib in second- or third-line therapy lived longer compared with those treated with Imbruvica. The study also showed that patients taking zanubrutinib went longer

Daraxonrasib has shown promising results in patients with previously treated RAS-mutated pancreatic ductal adenocarcinoma (PDAC), according to a Phase 1/2 study published in the New England Journal of Medicine. The drug works by blocking the active “ON” state of RAS proteins, helping stop cancer growth signals. In second-line treatment, patients with RAS G12 mutations achieved